Literature DB >> 21803451

Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice.

Chanpreet Singh1, Lifei Liu, Jun Ming Wang, Ronald W Irwin, Jia Yao, Shuhua Chen, Sherry Henry, Richard F Thompson, Roberta Diaz Brinton.   

Abstract

We previously demonstrated that allopregnanolone (APα) increased proliferation of neural progenitor cells and reversed neurogenic and cognitive deficits prior to Alzheimer's disease (AD) pathology (Wang, J.M., Johnston, P.B., Ball, B.G., Brinton, R.D., 2005. The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. J. Neurosci. 25, 4706-4718; Wang, J.M., Singh, C., Liu, L., Irwin, R.W., Chen, S., Chung, E.J., Thompson, R.F., Brinton, R.D., 2010. Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 107, 6498-6503). Herein, we determined efficacy of APα to restore neural progenitor cell survival and associative learning and memory subsequent to AD pathology in male 3xTgAD mice and their nontransgenic (nonTg) counterparts. APα significantly increased survival of bromodeoxyuridine positive (BrdU+) cells and hippocampal-dependent associative learning and memory in 3xTgAD mice in the presence of intraneuronal amyloid beta (Aβ) whereas APα was ineffective subsequent to development of extraneuronal Aβ plaques. Restoration of hippocampal-dependent associative learning was maximal by the first day and sustained throughout behavioral training. Learning and memory function in APα-treated 3xTgAD mice was 100% greater than vehicle-treated and comparable to maximal normal nonTg performance. In aged 15-month-old nonTg mice, APα significantly increased survival of bromodeoxyuridine-positive cells and hippocampal-dependent associative learning and memory. Results provide preclinical evidence that APα promoted survival of newly generated cells and restored cognitive performance in the preplaque phase of AD pathology and in late-stage normal aging.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21803451      PMCID: PMC3232295          DOI: 10.1016/j.neurobiolaging.2011.06.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  70 in total

1.  Neurogenesis in the adult is involved in the formation of trace memories.

Authors:  T J Shors; G Miesegaes; A Beylin; M Zhao; T Rydel; E Gould
Journal:  Nature       Date:  2001-03-15       Impact factor: 49.962

Review 2.  Neurosteroids: biochemistry and clinical significance.

Authors:  Synthia H Mellon; Lisa D Griffin
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

Review 3.  Neurogenesis in the adult brain.

Authors:  Fred H Gage
Journal:  J Neurosci       Date:  2002-02-01       Impact factor: 6.167

4.  Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice.

Authors:  Lauren M Billings; Kim N Green; James L McGaugh; Frank M LaFerla
Journal:  J Neurosci       Date:  2007-01-24       Impact factor: 6.167

5.  Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients.

Authors:  Sébastien Weill-Engerer; Jean-Philippe David; Véronique Sazdovitch; Philippe Liere; Bernard Eychenne; Antoine Pianos; Michael Schumacher; André Delacourte; Etienne-Emile Baulieu; Yvette Akwa
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

6.  Age-dependent impairment of delay and trace eyeblink conditioning in mice.

Authors:  Y Kishimoto; M Suzuki; S Kawahara; Y Kirino
Journal:  Neuroreport       Date:  2001-10-29       Impact factor: 1.837

Review 7.  Neurosteroids: beginning of the story.

Authors:  E E Baulieu; P Robel; M Schumacher
Journal:  Int Rev Neurobiol       Date:  2001       Impact factor: 3.230

8.  FGF-2-responsive neural stem cell proliferation requires CCg, a novel autocrine/paracrine cofactor.

Authors:  P Taupin; J Ray; W H Fischer; S T Suhr; K Hakansson; A Grubb; F H Gage
Journal:  Neuron       Date:  2000-11       Impact factor: 17.173

9.  Long-lasting impairment in hippocampal neurogenesis associated with amyloid deposition in a knock-in mouse model of familial Alzheimer's disease.

Authors:  Chen Zhang; Elizabeth McNeil; Lindsay Dressler; Robert Siman
Journal:  Exp Neurol       Date:  2006-10-27       Impact factor: 5.330

10.  Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis.

Authors:  Laure Verret; Joanna L Jankowsky; Guilian M Xu; David R Borchelt; Claire Rampon
Journal:  J Neurosci       Date:  2007-06-20       Impact factor: 6.167

View more
  51 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Allopregnanolone increases the number of dopaminergic neurons in substantia nigra of a triple transgenic mouse model of Alzheimer's disease.

Authors:  Chenyou Sun; Xiaoming Ou; Jerry M Farley; Craig Stockmeier; Steven Bigler; Roberta Diaz Brinton; Jun Ming Wang
Journal:  Curr Alzheimer Res       Date:  2012-05       Impact factor: 3.498

3.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

4.  Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease.

Authors:  Shuhua Chen; Tian Wang; Jia Yao; Roberta Diaz Brinton
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

5.  Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice.

Authors:  Russell Palm; Jaewon Chang; Jeffrey Blair; Yoelvis Garcia-Mesa; Hyoung-Gon Lee; Rudy J Castellani; Mark A Smith; Xiongwei Zhu; Gemma Casadesus
Journal:  J Neurochem       Date:  2014-04-02       Impact factor: 5.372

Review 6.  Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases.

Authors:  Ajay Kumar; Karthikeyan Narayanan; Ravi Kumar Chaudhary; Sachin Mishra; Sundramurthy Kumar; Kumar Jayaseelan Vinoth; Parasuraman Padmanabhan; Balázs Gulyás
Journal:  Mol Neurobiol       Date:  2016-11-04       Impact factor: 5.590

7.  Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Authors:  David Baglietto-Vargas; Rodrigo Medeiros; Hilda Martinez-Coria; Frank M LaFerla; Kim N Green
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

8.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

9.  Age-related changes in neuroactive steroid levels in 3xTg-AD mice.

Authors:  Donatella Caruso; Anna M Barron; Meghan A Brown; Federico Abbiati; Paloma Carrero; Christian J Pike; Luis M Garcia-Segura; Roberto C Melcangi
Journal:  Neurobiol Aging       Date:  2012-11-02       Impact factor: 4.673

Review 10.  Progestogens' effects and mechanisms for object recognition memory across the lifespan.

Authors:  Alicia A Walf; Carolyn J Koonce; Cheryl A Frye
Journal:  Behav Brain Res       Date:  2015-07-30       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.